hahaha.....I know after the run, you just couldn't resist the short." It can't continue this! it just can't. This is begging to be shorted!" then came today's blow out earnings and she adds 6%. The Queen takes out the bishop.
classic FUD piece to drive panic sells so that they can close out their short before the BOOM!
Don't they make up their own stuff anymore? MF now has to plagiarizer concepts from a Seeking Alpha author.
hey all in afrezza, I thought you said you went all out at 9.25 on May 30. What are you hanging around here for. you should be out on your boat.
Here's a thought. It's not a matter of guessing exit price. It's a matter of time. The next 18 months are going to be impactful starting Monday. Shorts covering and newbies entering. Upgrades and new analyst coverage. Partnership with an up front of between $300-500M. Production ramp and the sales in 1h 2015. The diabetic community buzzing "who has tried this inhalable insulin?" Public Advertising and education of PCP's and endos. Sale results and demand outlook ( this is where any potential downturn risk may lay) Don't limit your Vision on this one. Mnkd ain't dndn. To exit earlier leaves much on the table. That's my thinking.
Afrezza has a Boxed Warning advising that acute bronchospasm has been observed in patients with asthma and chronic obstructive pulmonary disease (COPD). Afrezza should not be used in patients with chronic lung disease, such as asthma or COPD because of this risk. The most common adverse reactions associated with Afrezza in clinical trials were hypoglycemia, cough, and throat pain or irritation.
The FDA approved Afrezza with a Risk Evaluation and Mitigation Strategy, which consists of a communication plan to inform health care professionals about the serious risk of acute bronchospasm associated with Afrezza.
The FDA is requiring the following post-marketing studies for Afrezza:
a clinical trial to evaluate pharmacokinetics, safety and efficacy in pediatric patients;
a clinical trial to evaluate the potential risk of pulmonary malignancy with Afrezza (this trial will also assess cardiovascular risk and the long-term effect of Afrezza on pulmonary function);
two pharmacokinetic-pharmacodynamic euglycemic glucose-clamp clinical trials, one to characterize dose-response and one to characterize within-subject variability.
Ive seen the total unapologetic cluster buster he has made with Mannkind (MNKD). question him or dare challenge him and he will berate and mock you. He is a total looser. I use him as a contraindication, whatever he says, do the opposite. He is as right as the proverbial broken clock.
You don't want to sell but you will if it goes below 9.75? Heheheh. Is that where you shorted mnkd? Thanks for the concern troll post
not the device, but manufacture of the Afrezza pre-packaged modules for the Dreamboat inhaler. It takes time to make a billion of 'em. hence the bottleneck reference
same thing 3 times. exactly. He also prefaced everything with "as most of the listeners already probably know". So he knew he was telling listeners what they already knew 3 times over. Yikes! Next time they should just let me do it. Ha!